Drug Excretion

Pharmacology: Principles and Practice

Volumn , Issue , 2009, Pages 175-199

  Taft, David R ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85060417169     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-369521-5.00009-9     Document Type: Chapter

References (71)

1. G. Gibson and P. Skett (2001) Introduction to Drug Metabolism 3rd ed. Cheltenham, UK: Nelson Thornes
2. Y. Kwon (2001) Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists Springer-Verlag
3. S. Matern, J.L. Boyer, D. Keppler and P.J. Meier-Abt (2001) Hepatobiliary Transport: From Bench to Bedside The Netherlands: Kluwer Academic Publishers, BV Falk Symposium, Volume 121A
4. M. Rogge and D. Taft (2005) Preclinical Drug Development Boca Raton, FL: Taylor and Francis
5. B. Wang, G. You and M. Morris (2007) Drug Transporters: Molecular Characterization and Role in Drug Disposition Hoboken: Wiley-Interscience
6. N. Anzai, Y. Kanai and H. Endou (2006) Organic anion transporter family: Current knowledge. Journal of Pharmacological Sciences 100 411-426.
7. A. Ayrton and P. Morgan (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica; The Fate of Foreign Compounds in Biological Systems 31 469-497.
8. L.Z. Benet and C.L. Cummins (2001) The drug efflux-metabolism alliance: Biochemical aspects. Advanced Drug Delivery Reviews 50 S3-S11.
9. P. Bonate, K. Reith and S. Weir (1998) Drug interactions at the renal level: Implications for drug development. Clinical Pharmacokinetics 34 375-404.
10. C.L. Booth, G.M. Pollack and K.L.R. Brouwer (1996) Hepatobiliary disposition of valproic acid and valproate glucoronide: Use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. Hepatol 23 771-780.
11. P. Borst and R. Oude Elferink (2002) Mammalian ABC transporters in health and disease. Annual Review of Biochemistry 71 537-592.
12. K.L.R. Brouwer and G.M. Pollack (2002) Pharmacogenomics: Is the right drug for the right patient sufficient? Advanced Drug Delivery Reviews 54 1243-1244.
13. P. Chandra and K.L.R. Boiuwer (2004) The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharmaceutical Research 21 719-735.
14. P.A. Chyka (1995) Multiple-dose activated charcoal and enhancement of systemic drug clearance: Summary of studies in animals and human volunteers. Journal of Toxicology. Clinical Toxicology 33 399-405.
15. S. Dallas, D.S. Miller and R. Bendayan (2006) Multidrug resistance-associated proteins: Expression and function in the central nervous system. Pharmacological Reviews 58 140-161.
16. M. Dresser, M.K. Leabman and K.M. Giacomini (2001) Transporters involved in the elimination of drugs in the kidney: Organic anion transporters and organic cation transporters. Journal of Pharmaceutical Sciences 90 397-421.
17. A.N. Elwi, V.L. Damaraju, S.A. Baldwin, J.D. Young, M.B. Sawyer and C.E. Cass (2006) Renal nucleoside transporters: Physiological and clinical implications. Biochemistry and Cell Biology = Biochimie et Biologie Cellulaire 84 844-858.
18. C.J. Endres, P. Hsiao, F.S. Chung and J.D. Unadkat (2006) The role of transporters in drug interactions. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 27 501-517.
19. K.N. Faber, M. Muller and P.L.M. Jansen (2003) Drug transport proteins in the liver. Advanced Drug Delivery Reviews 33 107-124.
20. K.N. Faber, M. Muller and P.L.M. Jansen (2003) Drug transport proteins in the liver. Advanced Drug Delivery Reviews 55 107-124.
21. M.A. Hediger, M.F. Romero, J.B. Peng, A. Rolfs, H. Takanaga and E.A. Bruford (2004) The ABCs of solute carriers: Physiological, pathological and therapeutic implications of human membrane transport proteins. Pflugers Archiv: European Journal of Physiology 447 465-468.
22. G.M. Heimer and D.E. Englund (1986) Enterohepatic recirculation of estriol: Inhibition by activated charcoal. Acta Endocrinologica 113 93-95.
23. E. Hood (2003) Pharmacogenomics: The prominse of personalized medicine. Environmental Health Perspectives 111 A581-A589.
24. K.I. Inui, S. Masuda and H. Saito (2000) Cellular and molecular aspects of drug transport in the kidney. Kidney International 58 944-958.
25. S. Ito and A. Lee (2003) Drug excretion into breast milk—overview. Advanced Drug Delivery Reviews 55 617-627.
26. H.L. Johnson and H.I. Maibach (1971) Drug excretion in human eccrine sweat. The Journal of Investigative Dermatology 56 182-188.
27. H. Kerb (2006) Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Letters 234 4-33.
28. K.T. Kivisto and M. Niemi (2006) Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharmaceutical Research 24 239-247.
29. H. Koepsell, K. Lips and C. Volk (2006) Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharmaceutical Research 24 1227-1251.
30. H. Kushuhara and Y. Sugiyama (2002) Role of transporters in the tissue-selective distribution and elimination of drugs: Transporters in the liver, small intestine, brain and kidney. Journal of Controlled Release: Official Journal of the Controlled Release Society 78 43-54.
31. H. Kushuhara, H. Suzuki and Y. Sugiyama (1998) The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatic excretion of drugs. Journal of Pharmaceutical Sciences 87 1025-1040.
32. Y.W.F. Lam, S. Banerji, C. Hatfield and R.L. Talbert (1997) Principles of drug administration in renal insufficiency. Clinical Pharmacokinetics 32 30-57.
33. J.H. Lin and M. Yamazaki (2003) Role of p-glycoprotein in pharmacokinetics: Clinical implications. Clinical Pharmacokinetics 42 59-98.
34. L. Liu and K.S. Pang (2005) The roles of transporters and enzymes in hepatic drug processing. DMD 33 1-9.
35. Q. Mao and J.D. Unadkat (2005) Role of the breast cancer resistance protein (abcg2) in drug transport. The AAPS Journal 7 E118-E133.
36. C. Marzolini, R.G. Tirona and R.B. Kim (2004) Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 5 273-282.
37. R. Masereeuw and F.G.M. Russel (2001) Mechanisms and clinical implications of renal drug excretion. Drug Metabolism Reviews 33 299-351.
38. D.K.F. Meijer, J.W. Smit and M. Muller (1997) Hepatobiliary elimination of cationic drugs: The role of P-glycoproteins and other ATP-dependent transporters. Advanced Drug Delivery Reviews 25 159-200.
39. G. Merino, A.E. van Herwaarden, E. Wagenaar, J.W. Jonker and A.H. Schinkel (2005) Sex-dependent expression and activity of the atp-binding cassette transporter breast cancer resistance protein (bcrp/abcg2) in liver. Molecular Pharmacology 67 1765-1771.
40. T. Mikkaichi, et al. (2004) The organic anion transporter (OATP) family. Drug Metabolism and Pharmacokinetics 1 171-179.
41. N. Mizuno, T. Niwa, Y. Yotsumoto and Y. Sugiyama (2003) Impact of drug transporter studies on drug discovery and development. Pharmacological Reviews 55 425-461.
42. N. Mizuno and Y. Sugiyama (2002) Drug trasnporters: Their role and importance in the selection and development of new drugs. Drug Metabolism and Pharmacokinetics 17 93-108.
43. T. Nakatani-Freshwater, M. Babayeva, A. Dontabhaktuni and D.R. Taft (2006) Effects of trimethoprim on the clearance of apricitabine, a deoxycytidine analog reverse transcriptase inhibitor, and Lamivudine in the isolated perfused rat kidney. The Journal of Pharmacology and Experimental Therapeutics 319 941-947.
44. H. Omote, M. Hiasa, T. Matsumoto, M. Otsuka and Y. Moriyama (2006) The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends in Pharmacological Sciences 27 587-593.
45. M. Otsuka, T. Matsumoto, R. Morimoto, S. Arioka, H. Omote and Y. Moriyama (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. PNAS 102 17928. 17928
46. R.P.J. Oude Elferink, D.K.F. Meijer, F. Kuipers, P.L.M. Jansen, A.K. Groen and G.M.M. Groothuis (1995) Hepatobiliary secretion of organic compounds; Molecular mechanisms of membrane transport. Biochimica et Biophysica Acta 1241 215-268.
47. K.S. Pang and M. Rowland (1977) Hepatic clearance of drugs I: Theoretical considerations of a “well-stirred” model and a “parallel-tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. Journal of Pharmacokinetics and Biopharmaceutics 5 625-653.
48. D. Perri, S. Ito, V. Rowsell and N.H. Shear (2003) The kidney? The body's playground for drugs: An overview of renal drug handling with selected clinical correlates. The Canadian Journal of Clinical Pharmacology = Journal Canadien de Pharmacologie Clinique 10 17-23.
49. B.J. Pleurvy (2005) Modes of drug elimination. Anaesthesia and Intensive Care Medicine 6 277-279.
50. J.B. Pritchard and D.S. Miller (1996) Renal secretion of organic anions and cations. Kidney International 49 1649-1654.
51. J.B. Pritchard and D.S. Miller (1997) Renal secretion of organic anions: A multistep process. Advanced Drug Delivery Reviews 25 231-242.
52. A.N. Rizwan and G. Burckhardt (2006) Organic anion transporters of the SLC22 family: Biopharmaceutical, physiological, and pathological roles. Pharmaceutical Research 24 1227-1251.
53. M.S. Roberts, B.M. Magnusson, F.J. Burczynski and M. Weiss (2002) Enterohepatic circulation: Physiological, pharmacokinetic and clinical implications. Clinical Pharmacokinetics 41 751-790.
54. E.E. Robertson and G.O. Rankin (2006) Human renal organic anion transporters: Characteristics and contributions to drug and drug metabolite excretion. Pharmacology & Therapeutics 109 399-412.
55. T. Sakaeda, T. Nakamura and K. Okumura (2003) Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4 397-410.
56. A.H. Schinkel and J.W. Jonker (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Advanced Drug Delivery Reviews 55 3-29.
57. T. Sekine, H. Miyazaki and H. Endou (2006) Molecular physiology of renal organic anion transporters. American Journal of Physiology. Renal Physiology 290 251-261.
58. Y. Shitara, T. Horie and Y. Sugiyama (2006) Transporters as a determinant of drug clearance and tissue distribution. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 27 425-446.
59. Y. Shitara, H. Sato and Y. Sugiyama (2005) Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annual Review of Pharmacology and Toxicology 45 689-723.
60. P. Statkevich, D.J. Fournier and K.R. Sweeney (1994) Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. The Journal of Pharmacology and Experimental Therapeutics 265 1118-1124.
61. H. Sun, L. Frassetto and L.Z. Benet (2006) Effects of renal failure on drug transport and metabolism. Pharmacology & Therapeutics 109 1-11.
62. H. Suzuki and Y. Sugiyama (2000) Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 12 3-12.
63. K.R. Sweeney, P.H. Hsyu, P. Statkevich and D.R. Taft (1995) Renal disposition and drug interaction screening of (-)-2′-deoxy-3′-thiacytidine (3TC) in the isolated perfused rat kidney. Pharmaceutical Research 12 1958-1963.
64. D.H. Sweet (2005) Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicology and Applied Pharmacology 204(3), 198-215.
65. D.R. Taft, A. Dontabhaktuni, M. Babayeva, T. Nakatani-Freshwater and I.A. Savant (2006) Application of the isolated perfused rat kidney model to assess gender effects on drug excretion. Drug Development and Industrial Pharmacy 32 919-928.
66. L. Tang, A.M. Persky, G. Hochhaus and B. Meibohm (2004) Pharmacokinetic aspects of biotechnology products. Journal of Pharmaceutical Sciences 93 2184-2204.
67. Y. Tanihara, S. Masuda, T. Sato, T. Katsura, O. Ogawa and K.I. Inui (2007) Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters Apr 13, 2007 (Epub ahead of print)
68. G.I. Tucker (1984) Measurement of the renal clearance of drugs. British Journal of Clinical Pharmacology 12 761-770.
69. S.H. Wright and W.H. Dantzler (2004) Molecular and cellular physiology of renal organic cation and anion transport. Physiological Reviews 84 987-1049.
70. M.J. Zamek-Gliszczynski, K.A. Hoffmaster, K. Nezasa, M.H. Tallman and K.L.R. Brouwer (2006) Integration of hepatic drug transporters and phase II metabolizing enzymes: Mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 27 447-486.
71. F. Zhou and G. You (2006) Molecular insights into the structure-function relationship of organic anion transporters OATs. Pharmaceutical Research 24 28-36.